Development of anti-IL-33 agent and application for prevention of early allergic disease
| Project/Area Number |
26670057
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
Shoji Shozo 熊本大学, 大学院生命科学研究部(薬), 名誉教授 (60040317)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | IL-33 |
|---|
| Outline of Final Research Achievements |
IL-33, a member of IL-1 family, is deeply associated with allergic reactions. In this study, we explored the anti-IL-33 agents. We established an in vitro assay system using KU812 cells that are known as immature human basophilic cell line to investigate the anti-IL-33 agents. Reported crystallographic structure of complex of IL-33 and the receptor ST2L was referred to select already known compounds or to synthesized novel compounds for the evaluation. As a result, two novel compounds, named Fi-10 and Fi-11, interestingly showed highest anti-IL-33 activity in the examined compounds in this study. It was suggested that the two compounds directly act to IL-33 to inhibit the activity. Further optimization of the chemical structure based on our results should be required to develop highly specific anti-IL-33 agents in the future.
|
Report
(3 results)
Research Products
(5 results)
